Tag Archives: cancer

Organovo Collaborates With Professor Melissa Little for Kidney Tissue Research

transforming treatment_cover

SAN DIEGO and MELBOURNE, Australia and SPRINGFIELD, Va., Jan. 24, 2017 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a collaboration with Professor Melissa Little and the Murdoch Childrens Research Institute, The Royal Children’s Hospital, Melbourne, Australia to develop an architecturally correct kidney for potential therapeutic applications.  The collaboration has been made possible by a generous gift from the Methuselah Foundation (“Methuselah”) as part of its ongoing University 3D Bioprinter Program.

“Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues,” said Keith Murphy, CEO, Organovo.  “This collaboration with Professor Little’s lab is another important step in this direction.  With the devoted and ongoing support of the Methuselah Foundation, leading researchers are able to leverage Organovo’s powerful technology platform to achieve significant breakthroughs.”

“We have developed an approach for recreating human kidney tissue from stem cells,” said Professor Melissa Little, Theme Director of Cell Biology at Murdoch Childrens Research Institute.  “Using Organovo’s bioprinter will give us the opportunity to bioprint these cells into a more accurate model of the kidney.  While initially important for modelling disease and screening drugs, we hope that this is also the first step towards regenerative medicine for kidney disease.  We are very grateful to Organovo and the Methuselah Foundation for this generous support, which will enable us to advance our research with the first Organovo bioprinter in the southern hemisphere.”

Under Methuselah Foundation’s University 3D Bioprinter Program, Methuselah is donating at least $500,000 in direct funding to be divided among several institutions for Organovo bioprinter research projects.  This funding will cover budgeted bioprinter costs and key aspects of project execution.

“We at the Methuselah Foundation have been a long-time supporter of academic and industry research in 3D bioprinting, regenerative medicine, and tissue engineering,” said David Gobel, CEO, Methuselah Foundation. “Our University 3D Bioprinter Program puts Organovo’s breakthrough 3D bioprinting technology in the hands of the brightest scientists at tissue engineering centers of excellence.”

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications.  The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners.  Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.  The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing.  The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications.  In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets.  Organovo is changing the shape of life science research and transforming medical care.  Learn more at www.organovo.com.

About Murdoch Childrens Research Institute

Murdoch Childrens undertakes research into infant, child and adolescent health.  As the largest child health research institute in Australia, our 1500 researchers are working hard to translate the knowledge we create from our research into effective prevention, early intervention and treatments for children.  We strive for a healthier community, fewer sick kids visiting hospitals, and the best possible care for children who unfortunately become ill.  The Murdoch Childrens has a proud history of scientific discovery since its inception in 1986, and is currently based at The Royal Children’s Hospital in Melbourne, Australia.  For more information please visit: www.mcri.edu.au.

About Methuselah Foundation

The Methuselah Foundation is a non-profit medical charity working to create a world where 90 year olds can have the health profile of 50 year olds, by 2030.  By opportunistically leveraging resources, enabling partnerships, and awarding prizes and grants, we accelerate disruptive developments in biomedical engineering that will eradicate needless suffering and extend healthy human life.  For more information please visit: www.methuselahfoundation.org and www.neworgan.org.

Scientists Correct Mutated Gene that Causes Sickle Cell Disease in Stem Cells

baby-sickle-vell

For the first time, scientists were able to correct the genetic mutation that causes sickle cell disease in stem cells.

In a collaborative effort, researchers at UC Berkeley, UC San Francisco Benioff Children’s Hospital Oakland Research Institute (CHORI), and the University of Utah School of Medicine fixed the mutation in modified stem cells from patients with the condition using a CRISPR/Cas9 gene editing approach.

The study, “Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells,” was published in the journal Science Translational Medicine.

The scientists hope to re-infuse patients with the modified stem cells and alleviate disease symptoms.

“We’re very excited about the promise of this technology,” Jacob Corn, senior author on the study and scientific director of the Innovative Genomics Initiative at UC Berkeley, said in a news release. “There is still a lot of work to be done before this approach might be used in the clinic, but we’re hopeful that it will pave the way for new kinds of treatment for patients with sickle cell disease.”

The researchers observed in mice tests that after transplants, the modified stem cells stuck around for about four months, an important target of the long-lasting potential of any therapy.

“This is an important advance because for the first time we show a level of correction in stem cells that should be sufficient for a clinical benefit in persons with sickle cell anemia,” said Mark Walters, a pediatric hematologist and oncologist and director of UCSF Benioff Oakland’s Blood and Marrow Transplantation Program and co-author of the study.

Read more info here

Episode 007 – Control Alt Delete Cancer Research into longevity, human health, ageing, New Organ Research including bioprinting liver, kidney, and other medical pursuits

 

Control Alt Del

Hello and welcome to Episode 7!  On this episode, we’ll talk with Dr. Haroldo Silva and David Halvorsen of the SENS Research Foundation.  They’ve launched a new crowdfunding campaign designed to attack and stop cancer using a new approach.  You’ll hear what that approach is, why they think it has a good chance of success, and you can help in the fight.

If you’d like to comment on the show, have a question or want to reach us, write Rod.Wheaton@MFoundation.org

To learn how you can help the Methuselah Foundation continue its mission to extend heathy human life, CLICK HERE

NASA’s Vascular Tissue Challenge to help in study of deep space environmental effects

NASA’s Vascular Tissue Challenge to help in study of deep space environmental effects

Those working in the field of bioengineering should be ready for a challenge worth $500,000. NASA, along with the nonprofit Methuselah Foundation’s New Organ Alliance, has introduced the new prize competition, named as the Vascular Tissue Challenge. The first three teams that will succeed in creating thick, metabolically-functional human vascularized organ tissue in a controlled laboratory environment will be offered the prize money.

The participants in the competition have to produce vascularized tissue that is more than .39 inches in thickness and one that would offer over 85% of survival to required cells throughout a 30-day trial period. The teams in order to succeed should conduct three trials with at least a 75% of success rate. Moreover, teams must submit a proposal on ways to advance some aspect of their research further through a microgravity experiment, which would be conducted in the US National Laboratory on the International Space Station.

Tissue is a combination of related cells joined together to function as…to read more, CLICK HERE

Longevity, ageing, research, cancer, new organs, bioprinting, nasa, sens, age, human, health,kidney,liver,transplant,organ,doctor,grants

Episode 006 – Could Cryopreservation for Human Organs Save 700,000 – 900,000 Lives a Year?

 

Transplanting Organs

Join us on this episode of the Methuselah 300 Podcast as we interview Dr. Sebastian Eriksson Giwa;  co-founder and chairman of the Organ Preservation Alliance and co-founder and CEO of Sylvatica Biotech.  Dr. Giwa will discuss how Cryopreservation could transform and revolutionize transplantation Currently at least 1 in 5 people on the organ waiting list die due to the inability of keeping organs viable for transport, resulting in 700,000 deaths a year by some estimates.  Dr Giwa and his team want to change that…

The Defense Department, National Science Foundation and even the White House are beginning to recognize the need and potential of this scientific frontier , and scientists from around the world to an increasing decree are tackling the remaining challenges.  

Will you join us?  You can find out how to become a foundation supporter at  Mfoundation.org.

We thank you for your support now and in the future!

Sincerely,

Methuselah Foundation

methuselah_itunes_logo

Episode 005 with Dr John Geibel; Yale University How Yale's Team of Researchers are Moving Toward 3-D Printable Organs

 

Faculty portraits
John Giebel, Director of Surgical Research, Yale University

On this week’s podcast, join us as we talk with Dr John Geibel, Director of Surgical Research and Professor of Department of Cellular and Molecular Physiology at Yale University.  Discover how his team is working hard to develop the first iterations of 3-D printable organs, a goal that will revolutionize the medical organ industry and save thousands upon thousands of lives.

To keep up with the latest developments, join our newsletter HERE

To find out how you can be a part of the Methuselah Foundation and support our work, go to Mfoundation.org or click HERE

Methuselah 300 Podcast Episode 004: Is a Synthetic Liver on the Horizon? With Dr Bryon Petersen A Synthetic Liver Could Bridge the Gap Between Now and the Development of an Real Tissue New Organ

Could this device bridge the gap to new organs?

Join us on this week’s podcast as we interview Dr. Bryon Petersen, who is researching and developing a new device that could bridge the gap for those awaiting a new liver so that those in need can have a quality of life impossible for them now.  You’ll here about where he is in the stage of development, and what timeline he is working toward.

To keep up with the latest developments, join our newsletter HERE

To find out how you can be a part of the Methuselah Foundation and support our work, go to Mfoundation.org or click HERE

methuselah_itunes_logo

Longevity, ageing, research, cancer, new organs, bioprinting, nasa, sens, age, human, health,kidney,liver,transplant,organ,doctor,grants